Cargando…

Chemokines in Gestational Diabetes Mellitus

BACKGROUND: Studies investigating chemokines in gestational diabetes mellitus (GDM) have yielded mixed results. The purpose of this meta-analysis was to explore whether concentrations of chemokines in patients with GDM differed from that of the controls. METHODS: Following Preferred Reporting Items...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hongying, Liu, Aizhong, Kaminga, Atipatsa C., McDonald, Judy, Wen, Shi Wu, Pan, Xiongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860907/
https://www.ncbi.nlm.nih.gov/pubmed/35211112
http://dx.doi.org/10.3389/fimmu.2022.705852
_version_ 1784654767541190656
author Liu, Hongying
Liu, Aizhong
Kaminga, Atipatsa C.
McDonald, Judy
Wen, Shi Wu
Pan, Xiongfeng
author_facet Liu, Hongying
Liu, Aizhong
Kaminga, Atipatsa C.
McDonald, Judy
Wen, Shi Wu
Pan, Xiongfeng
author_sort Liu, Hongying
collection PubMed
description BACKGROUND: Studies investigating chemokines in gestational diabetes mellitus (GDM) have yielded mixed results. The purpose of this meta-analysis was to explore whether concentrations of chemokines in patients with GDM differed from that of the controls. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Web of Science, Embase, Cochrane Library, and PubMed databases for articles, published in any language, on chemokines and GDM through August 1st, 2021. The difference in concentrations of chemokines between patients with GDM and controls was determined by a standardized mean difference (SMD) with a 95% confidence interval (CI), calculated in the meta-analysis of the eligible studies using a random-effects model with restricted maximum-likelihood estimator. RESULTS: Seventeen studies met the inclusion criteria for the meta-analysis. Altogether, they included nine different chemokines comparisons involving 5,158 participants (1,934 GDM patients and 3,224 controls). Results showed a significant increase of these chemokines (CCL2, CXCL1, CXCL8, CXCL9, and CXCL12) in the GDM patients compared with the controls. However, there was a significant decrease of the chemokines, CCL4, CCL11 and CXCL10, in the GDM patients compared with the controls. Moreover, subgroup analysis revealed a potential role of chemokines as biomarkers in relation to laboratory detection (different sample type and assay methods) and clinical characteristics of GDM patients (ethnicity and body mass index). CONCLUSION: GDM is associated with several chemokines (CCL2, CCL4, CCL11, CXCL1, CXCL8, CXCL9, CXCL10 and CXCL12). Therefore, consideration of these chemokines as potential targets or biomarkers in the pathophysiology of GDM development is necessary. Notably, the information of subgroup analysis underscores the importance of exploring putative mechanisms underlying this association, in order to develop new individualized clinical and therapeutic strategies.
format Online
Article
Text
id pubmed-8860907
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88609072022-02-23 Chemokines in Gestational Diabetes Mellitus Liu, Hongying Liu, Aizhong Kaminga, Atipatsa C. McDonald, Judy Wen, Shi Wu Pan, Xiongfeng Front Immunol Immunology BACKGROUND: Studies investigating chemokines in gestational diabetes mellitus (GDM) have yielded mixed results. The purpose of this meta-analysis was to explore whether concentrations of chemokines in patients with GDM differed from that of the controls. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Web of Science, Embase, Cochrane Library, and PubMed databases for articles, published in any language, on chemokines and GDM through August 1st, 2021. The difference in concentrations of chemokines between patients with GDM and controls was determined by a standardized mean difference (SMD) with a 95% confidence interval (CI), calculated in the meta-analysis of the eligible studies using a random-effects model with restricted maximum-likelihood estimator. RESULTS: Seventeen studies met the inclusion criteria for the meta-analysis. Altogether, they included nine different chemokines comparisons involving 5,158 participants (1,934 GDM patients and 3,224 controls). Results showed a significant increase of these chemokines (CCL2, CXCL1, CXCL8, CXCL9, and CXCL12) in the GDM patients compared with the controls. However, there was a significant decrease of the chemokines, CCL4, CCL11 and CXCL10, in the GDM patients compared with the controls. Moreover, subgroup analysis revealed a potential role of chemokines as biomarkers in relation to laboratory detection (different sample type and assay methods) and clinical characteristics of GDM patients (ethnicity and body mass index). CONCLUSION: GDM is associated with several chemokines (CCL2, CCL4, CCL11, CXCL1, CXCL8, CXCL9, CXCL10 and CXCL12). Therefore, consideration of these chemokines as potential targets or biomarkers in the pathophysiology of GDM development is necessary. Notably, the information of subgroup analysis underscores the importance of exploring putative mechanisms underlying this association, in order to develop new individualized clinical and therapeutic strategies. Frontiers Media S.A. 2022-02-08 /pmc/articles/PMC8860907/ /pubmed/35211112 http://dx.doi.org/10.3389/fimmu.2022.705852 Text en Copyright © 2022 Liu, Liu, Kaminga, McDonald, Wen and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Liu, Hongying
Liu, Aizhong
Kaminga, Atipatsa C.
McDonald, Judy
Wen, Shi Wu
Pan, Xiongfeng
Chemokines in Gestational Diabetes Mellitus
title Chemokines in Gestational Diabetes Mellitus
title_full Chemokines in Gestational Diabetes Mellitus
title_fullStr Chemokines in Gestational Diabetes Mellitus
title_full_unstemmed Chemokines in Gestational Diabetes Mellitus
title_short Chemokines in Gestational Diabetes Mellitus
title_sort chemokines in gestational diabetes mellitus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860907/
https://www.ncbi.nlm.nih.gov/pubmed/35211112
http://dx.doi.org/10.3389/fimmu.2022.705852
work_keys_str_mv AT liuhongying chemokinesingestationaldiabetesmellitus
AT liuaizhong chemokinesingestationaldiabetesmellitus
AT kamingaatipatsac chemokinesingestationaldiabetesmellitus
AT mcdonaldjudy chemokinesingestationaldiabetesmellitus
AT wenshiwu chemokinesingestationaldiabetesmellitus
AT panxiongfeng chemokinesingestationaldiabetesmellitus